Evidence map›Paper›PMID 38076279›Full record

ArticleMatrix biology plus2023

Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development.

Athiramol Sasi, Andreas Romaine, Pugazendhi Murugan Erusappan, Arne Olav Melleby, Almira Hasic, Christen Peder Dahl, Kaspar Broch, Vibeke Marie Almaas, Rosa Doñate Puertas, H Llewelyn Roderick and 4 more

Open access · goldAbstract read
In one paragraph

Article in Matrix biology plus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. From bump to pump: extracellular matrix remodeling, dynamics, and biomechanics in the maternal heart.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  2. Effects of faba beans (Food chemistry. Molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Athiramol SasiInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Andreas RomaineInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Pugazendhi Murugan ErusappanInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Arne Olav MellebyInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Almira HasicInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Christen Peder DahlResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Kaspar BrochK.G. Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
Vibeke Marie AlmaasDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Rosa Doñate PuertasExperimental Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
H Llewelyn RoderickK.G. Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
Ida Gjervold LundeInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ivar SjaastadInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Maria VistnesInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Geir ChristensenInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Oslo University Hospital · NOKU Leuven · BEUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac fibrosis is a central pathological feature in several cardiac diseases, but the underlying molecular players are insufficiently understood. The extracellular matrix proteoglycan versican is elevated in heart failure and suggested to be a target for treatment. However, the temporal expression and spatial distribution of versican and the versican cleavage fragment containing the neoepitope DPEAAE in cardiac fibrosis remains to be elucidated. In this study, we have examined versican during cardiac fibrosis development in a murine pressure overload model and in patients with cardiomyopathies. We found that versican, mainly the V1 isoform, was expressed immediately after induction of pressure overload, preceding collagen accumulation, and versican protein levels extended from the perivascular region into the cardiac interstitium. In addition, we found increased production of versican by collagen expressing fibroblasts, and that it was deposited extensively in the fibrotic extracellular matrix during pressure overload. In cardiac cell cultures, the expression of versican was induced by the pro-fibrotic transforming growth factor beta and mechanical stretch. Furthermore, we observed that the proteolytic cleavage of versican (DPEAAE fragment) increased in the late phase of fibrosis development during pressure overload. In patients with hypertrophic and dilated cardiomyopathies, we found elevated levels of versican and a positive correlation between versican and collagen mRNA in the heart, as well as increased cleavage of full-length protein. Taken together, the temporal expression profile and the spatial distribution of both the full-length versican and the DPEAAE fragment observed in this study indicates a role for versican in development of cardiac fibrosis.

Indexed as

Cardiac fibrosisCardiomyopathyExtracellular matrixPressure overloadVersican

Identifiers

PMID38076279
PMCPMC10709089
OpenAlexW4388561238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.